82454-61-3

Basic information

• Product Name: 5-ethynyl-2-pyridinaMine
• Synonyms: 5-ethynyl-2-pyridinaMine;2-aMino-5-ethynylpyridine;5-Ethynylpyridin-2-aMine
• CAS NO: 82454-61-3
• Molecular Formula: C₇H₆N₂
• Molecular Weight: 118.13594
• Mol File: 82454-61-3.mol

Chemical Properties

• Boiling Point: 254°C at 760 mmHg
• Flash Point: 107.4°C
• Appearance: /
• Vapor Pressure: 0.014mmHg at 25°C
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 5-ethynyl-2-pyridinaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-ethynyl-2-pyridinaMine(82454-61-3)
• EPA Substance Registry System: 5-ethynyl-2-pyridinaMine(82454-61-3)

Safety Data

• Hazardous Substances Data: 82454-61-3(Hazardous Substances Data)

Usage

Uses

5-Ethynyl-2-pyridinamine (CAS:82454-61-3) is a useful research compound.

InChI:InChI=1/C8H15NO2.ClH/c1-2-11-8(10)7-4-3-5-9-6-7;/h7,9H,2-6H2,1H3;1H/t7-;/m1./s1

Upstream product

• 457628-40-9 5-[(trimethylsilyl)ethynyl]pyridine-2-amine 
• 926009-62-3 N-(5-trimethylsilanylethynylpyridin-2-yl)formamide 
• 1072-97-5 5-bromo-2-pyridylamine 
• 141354-32-7 N-(5-bromopyridin-2-yl)formamide 
• 20511-12-0 2-amino-5-iodopyridine 
• 911114-11-9 C₁₀H₁₂N₂O 

Downstream Products

• 1134216-40-2 1-(2-methylthiophenyl)-2-(2-aminopyrid-5-yl)acetylene 
• 1134216-50-4 1-(3-methylthiophenyl)-2-(2-aminopyrid-5-yl)acetylene 
• 1367695-09-7 C₂₂H₂₆N₈O₆S 
• 1383744-39-5 C₁₈H₁₈F₂N₆O₃S 
• 1428445-69-5 C₂₅H₂₇F₃N₈O 
• 911115-16-7 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-y1]ethynyl]-2-pyridinamine 
• 329794-06-1 3-(6-Amino-pyridin-3-yl)-prop-2-yn-1-ol 

Relevant articles and documents

Ruthenium(II)-2, 2′-bipyridine/1, 10-phenanthroline complexes incorporating (E)-2-(((5-((4-methoxyphenyl)ethynyl)pyridin-2-yl)imino)methyl)-4-((4-nitro phenyl)ethynyl)phenol as a ligand

A new series of hexa-coordinated Ru(II) complexes of the type [Ru(L)(phen)2]X (1a–d) and [Ru(L)(bipy)2]X (2a–d) (where phen = 1,10-phenanthroline, bipy = 2,2′-bipyridine, X = NO3, BF4, ClO4, PF6) have been prepared by the reaction of (E)-2-(((5-((4-methoxyphenyl)ethynyl)pyridin-2-yl)imino)methyl)-4-((4-nitrophenyl)ethynyl)phenol (L) with [Ru(phen)2]Cl2·2H2O and [Ru(bipy)2]Cl2·2H2O. The complexes were characterized by physico-chemical and spectroscopic methods. All complexes are 1:1 conducting and diamagnetic in nature. In acetonitrile solution, the complexes displayed one reversible Ru(II)–Ru(III) oxidation couple and one irreversible Ru(III)–Ru(IV) oxidation and are sensitive to π-acidic character of phen and bipy ligands. The complexes show room-temperature luminescence originated from the lowest energy metal-to-ligand charge transfer excited state and are sensitive to difference in size of the counter anions. All the complexes displayed second harmonic generation by Kurtz-powder technique indicating their potential for the application as a useful NLO material.

Ru(II)-polypyridine complexes with alkynyl Schiff base ligand: influence of π-conjugation, donor/acceptor substituents, and counter anions on electrochemical, luminescence, and catalytic properties

Ru(II)-polypyridine complexes of the general formula [Ru(L1/L2)(phen)2]X2 (1a–6a) and [Ru(L1/L2)(bipy)2]X2 (1b–6b) (where X = ClO4, BF4, PF6; phen = 1,10-phenanthroline, bipy = 2,2′-bipyridine) were prepared by the reaction of [Ru(phen)2Cl2]·2H2O and [Ru(bipy)2Cl2]·2H2O with (E)-5-((4-methoxyphenyl)ethynyl)-N-(pyridin-2-ylmethylene)pyridin-2-amine (L1) and (E)-5-((4-nitrophenyl)ethynyl)-N-(pyridin-2-ylmethylene)pyridine-2-amine (L2) in the presence of NaBF4, NaClO4, and NaPF6. The electrochemical properties of all the complexes indicate reversible redox behavior corresponding to Ru(II)–Ru(III) couple and are susceptible to variation of electron-donating/accepting properties of substituent group on L1 and L2. All complexes showed room temperature luminescence corresponding to π→π* intra-ligand charge-transfer (ILCT) transition with chelation enhanced fluorescence and is finely tuned by increasing π-conjugation, size of counter anions, and variation of substituent group with different electronic effects in the complexes. All the complexes worked as an effective catalyst for the oxidation of benzyl alcohol to corresponding benzaldehyde in good yield at room temperature. (Figure presented.).

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.

ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF

The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.

Enhanced kinetic stability of [Pd2L4]4+ cages through ligand substitution

There is considerable interest in exploiting metallosupramolecular cages as drug delivery vectors. Recently, we developed a [Pd2L4]4+ cage capable of binding two molecules of cisplatin. Unfortunately, this first generation cage was rapidly decomposed by common biologically relevant nucleophiles. In an effort to improve the kinetic stability of these cage architectures here we report the synthesis of two amino substituted tripyridyl 2,6-bis(pyridin-3-ylethynyl)pyridine (tripy) ligands (with amino groups either in the 2-(2A-tripy) or 3-(3A-tripy) positions of the terminal pyridines) and their respective [Pd2(Ltripy)4]4+ cages. These systems have been characterised by 1H, 13C and DOSY NMR spectroscopies, high resolution electrospray mass spectrometry, elemental analysis and, in one case, by X-ray crystallography. It was established, using model palladium(ii) N-heterocyclic carbene (NHC) probe complexes, that the amino substituted compounds were stronger donor ligands than the parent system (2A-tripy > 3A-tripy > tripy). Competition experiments with a range of nucleophiles showed that these substitutions lead to more kinetically robust cage architectures, with [Pd2(2A-tripy)4]4+ proving the most stable. Biological testing on the three ligands and cages against A549 and MDA-MB-231 cell lines showed that only [Pd2(2A-tripy)4]4+ exhibited any appreciable cytotoxicity, with a modest IC50 of 36.4 ± 1.9 μM against the MDA-MB-231 cell line. Unfortunately, the increase in kinetic stability of the [Pd2(Ltripy)4]4+ cages was accompanied by loss of cisplatin-binding ability. FOR VERIFICATION The Royal Society of Chemistry.

METHODS FOR THE PREPARATION OF 5-[2-[7 (TRIFLUOROMETHYL)-5-[4- (TRIFLUOROMETHYL)PHENYL]PYRAZOLO [1,5-A]PYRIMIDIN-3-YL]ETHYNYL]-2-PYRIDINAMINE

The present invention provides methods for preparing 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine (compound A), which is useful for the treatment of depression and other CNS disorders. The present methods are useful for preparing compound A on large scale in manufacturing facilities.

Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform

Drug discovery faces economic and scientific imperatives to deliver lead molecules rapidly and efficiently. Using traditional paradigms the molecular design, synthesis, and screening loops enforce a significant time delay leading to inefficient use of data in the iterative molecular design process. Here, we report the application of a flow technology platform integrating the key elements of structure-activity relationship (SAR) generation to the discovery of novel Abl kinase inhibitors. The platform utilizes flow chemistry for rapid in-line synthesis, automated purification, and analysis coupled with bioassay. The combination of activity prediction using Random-Forest regression with chemical space sampling algorithms allows the construction of an activity model that refines itself after every iteration of synthesis and biological result. Within just 21 compounds, the automated process identified a novel template and hinge binding motif with pIC50 > 8 against Abl kinase - both wild type and clinically relevant mutants. Integrated microfluidic synthesis and screening coupled with machine learning design have the potential to greatly reduce the time and cost of drug discovery within the hit-to-lead and lead optimization phases.

NEW TRIAZOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

The present invention encompasses compounds of general formula (I) wherein the groups R2 to R4, A,X and m are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain compounds of this kind and their use as medicaments.

5-ALKYNYL-PYRIMIDINES

The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

5-ALKYNYL-PYRIMIDINES

The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.